25 NOVEMBER 2026

ASX RELEASE

CHANGE OF DIRECTOR'S INTEREST NOTICES – APPENDIX 3Y

Melbourne, Australia: Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) ("Amplia" or the "Company") provides Change of Director's Interest Notices - Appendix 3Y for the following Directors:

Ms Jane Bell
Dr Chris Burns
Dr Robert Peach
Dr Warwick Tong
Mr Brett Carter

The changes referred to in each of these notices relates to the issue of Zero Price Exercise Options with an expiry date of 9 September 2031 which were issued to Directors on 9 September 2026 following shareholder approval at the Company's Annual General Meeting on 28 August 2026.

The release of these Notices to the ASX should have been made on or before 16 September 2026. The delay in releasing these Notices is due entirely to an oversight on the part of the Company Secretary. The Company has a Continuous Disclosure Policy which functions well in the ordinary course of business. The Company notes that its Appendix 3G – Notification of issue of unquoted equity securities released to the market on 9 September 2026 fully disclosed the issue of these Zero Price Exercise Options to each of the Directors concerned.

The Company has taken steps to ensure that similar delays in the release of announcements do not occur in the future including the establishment of an appropriate checklist relating to the issue of new equity securities to Directors. The Company also has written agreements in place with each of the Directors to ensure that they disclose all of the information required by the Company so that the Company can meet its reporting obligations under 3.19A and the Directors of the Company have always complied with their obligations in this regard.

This ASX announcement was approved and authorised for release by the Chair of the Board and the Managing Director of Amplia Therapeutics.

ABN 16 165 160 841

+61 (0) 3 9123 1140 | info@ampliatx.com
Level 5, 90 William Street, Melbourne VIC 3000 Australia

www.ampliatx.com

Investor Contact:
Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

U.S. Contact:
Robert Giordano
rjgiordano@ggrouplifesciences.com
+1 917 327 3938

Media Contact:
Hannah Howlett, Titch Comms
Hannah@titchcomms.com.au
+61 450 648 064

ANZGOG Media Contact:
Monique Cerreto
Monique.cerreto@anzgog.org.au
+61 416 282 464

U.S. Media:
media@ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit **www.ampliatx.com** and follow Amplia on X (@ampliatx) and **LinkedIn**.

About Narmafotinib

Narmafotinib (AMP945) is the company's best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently undergoing a clinical trial (the **ACCENT** trial) where it is dosed in combination with the chemotherapies gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The trial has achieved its desired outcome in achieving a confirmed response rate of 36%, superior to chemotherapy alone, and a mOS of 11.1 months has been reported. Additional clinical studies in lung and ovarian cancer are in late-stage planning with further information available on the Company's website **www.ampliatx.com**.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**AMPLIA THERAPEUTICS LIMITED**
ABN	**16 165 160 841**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	**Jane Catherine Bell**
Date of last notice	8 September 2025

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	9 September 2026
No. of securities held prior to change	Jane Catherine Bell 485,036 Ordinary Shares Jane Catherine Bell & Geoffrey Bell <Schooner Super Fund A/C> 3,176,715 Ordinary Shares 240,590 Unlisted Options Ex Price $0.30 Exp 30 Sep 2028 521,739 Listed Options Ex Price $0.1725 Exp 31 Oct 2027
Class	Zero Exercise Price Options Exp 9 Sep 2031
Number acquired	642,857
Number disposed	Nil

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil – approved by shareholders at Annual General Meeting held 28 August 2026
No. of securities held after change	Jane Catherine Bell 485,036 Ordinary Shares 642,857 Zero Exercise Price Options Exp 9 Sep 2031 Jane Catherine Bell & Geoffrey Bell <Schooner Super Fund A/C> 3,176,715 Ordinary Shares 240,590 Unlisted Options Ex Price $0.30 Exp 30 Sep 2028 521,739 Listed Options Ex Price $0.1725 Exp 31 Oct 2027
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Approved by shareholders at Annual General Meeting held 28 August 2026

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

25 November 2026

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**Amplia Therapeutics Limited**
ABN	16 165 160 841

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	**Christopher John Burns**
Date of last notice	8 September 2025

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	9 September 2026
No. of securities held prior to change	4,155,574 Fully Paid Ordinary Shares 447,000 Unlisted Options - Nil Exercise Price Expiry Date 30 Sep 2028 2,500,000 Unlisted Options Exercise Price $0.135 Expiry Date 5 June 2028 260,869 Listed Options Ex Price $0.1725 Exp 31 Oct 2027
Class	Zero Exercise Price Options Exp 9 Sep 2031
Number acquired	687,772
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil – approved by shareholders at Annual General Meeting held 28 August 2026

+ See chapter 19 for defined terms.

No. of securities held after change	4,155,574 Fully Paid Ordinary Shares 447,000 Unlisted Options - Nil Exercise Price Expiry Date 30 Sep 2028 2,500,000 Unlisted Options Exercise Price $0.135 Expiry Date 5 June 2028 260,869 Listed Options Ex Price $0.1725 Exp 31 Oct 2027 687,772 Zero Exercise Price Options Exp 9 Sep 2031
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Approved by shareholders at Annual General Meeting held 28 August 2026

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

25 November 2026

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**Amplia Therapeutics Limited**
ABN	16 165 160 841

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	**Dr. Robert Peach**
Date of last notice	8 September 2025

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Cofactor LLC of which Dr. Peach is a Director and owner
Date of change	9 September 2026
No. of securities held prior to change	Andrea Marie Peach and Robert James Peach <Peach Family Trust> 4,798,212 Shares 815,218 Listed Options Ex Price $0.1725 Exp 31 Oct 2027 240,590 Unlisted Options Ex Price $0.30 Exp 30 Sep 2028 Cofactor LLC – 1,332,952 Shares
Class	Zero Exercise Price Options Exp 9 Sep 2031
Number acquired	500,000
Number disposed	Nil

+ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil – approved by shareholders at Annual General Meeting held 28 August 2026
No. of securities held after change	Andrea Marie Peach and Robert James Peach <Peach Family Trust> 4,798,212 Shares 815,218 Listed Options Ex Price $0.1725 Exp 31 Oct 2027 240,590 Unlisted Options Ex Price $0.30 Exp 30 Sep 2028 500,000 Zero Exercise Price Options Exp 9 Sep 2031 Cofactor LLC – 1,332,952 Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Approved by shareholders at Annual General Meeting held 28 August 2026

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	-
Name of registered holder (if issued securities)	-
Date of change	-
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	-
Interest acquired	-
Interest disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	-
Interest after change	-

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	-
If prior written clearance was provided, on what date was this provided?	-

25 November 2026

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**Amplia Therapeutics Limited**
ABN	16 165 160 841

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	**Warwick Bonner Tong**
Date of last notice	8 September 2025

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	9 September 2026
No. of securities held prior to change	WARWICK TONG 2,355,140 Fully Paid Ordinary Shares DR WARWICK BONNER TONG & MRS DEBRA ANN TONG <DEBWAR SUPERANNUATION A/C> 1,508,933 Fully Paid Shares 336,826 Unlisted Options Ex Price $0.30 Exp 30 Sep 2028 521,739 Listed Options Ex Price $0.1725 Exp 31 Oct 2027
Class	Zero Exercise Price Options Exp 9 Sep 2031
Number acquired	500,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil – approved by shareholders at Annual General Meeting held 28 August 2026

+ See chapter 19 for defined terms.

No. of securities held after change	WARWICK TONG 2,355,140 Fully Paid Ordinary Shares 500,000 Zero Exercise Price Options Exp 9 Sep 2031 DR WARWICK BONNER TONG & MRS DEBRA ANN TONG <DEBWAR SUPERANNUATION A/C> 1,508,933 Fully Paid Shares 336,826 Unlisted Options Ex Price $0.30 Exp 30 Sep 2028 521,739 Listed Options Ex Price $0.1725 Exp 31 Oct 2027
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Approved by shareholders at Annual General Meeting held 28 August 2026

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

25 November 2026

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**Amplia Therapeutics Limited**
ABN	16 165 160 841

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	**Brett Anthony Carter**
Date of last notice	8 July 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Beneficiary of Bioseer Family Ac
Date of change	9 September 2026
No. of securities held prior to change	Nil
Class	Zero Exercise Price Options Exp 9 Sep 2031
Number acquired	500,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil – approved by shareholders at Annual General Meeting held 28 August 2026

+ See chapter 19 for defined terms.

No. of securities held after change	Joyce Lam <Bioseer Family Ac> 500,000 Zero Exercise Price Options Exp 9 Sep 2031
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Approved by shareholders at Annual General Meeting held 28 August 2026

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

25 November 2026

+ See chapter 19 for defined terms.